financial guidance

The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.

Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected. 

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

The firm said revenues fell because of delayed shipments of HIV self-tests and ongoing softness in the consumer genomics markets.

The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.